Trials / Completed
CompletedNCT00622063
An Extension Study for Patients Previously Treated With ARQ 501
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARQ 501 | Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2008-09-01
- First posted
- 2008-02-22
- Last updated
- 2013-02-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00622063. Inclusion in this directory is not an endorsement.